• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    9/11/23 6:01:04 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email
    SC 13D/A 1 p23-2372sc13da.htm ANIKA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
     

    Anika Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    035255108

    (CUSIP Number)
     
    David Johnson
    Caligan Partners LP
    515 Madison Avenue, 8th Floor
    New York, NY 10022
    (646) 859-8204
     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    September 8, 2023

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     

    (Page 1 of 7 Pages)

    ______________________________

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Caligan Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,081,360 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,081,360 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,081,360 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.4%

    14

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     
     

     

     

    1

    NAME OF REPORTING PERSON

    David Johnson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x
    (b) ¨
    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,081,360 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,081,360 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,081,360 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.4%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     
     

     

    This Amendment No. 1 (“Amendment No.1”) amends and supplements the statement on Schedule 13D filed by the undersigned on August 17, 2023 (the “Original Schedule 13D” and, together with Amendment No. 1, the “Schedule 13D”) as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
    The first sentence of Item 3 is hereby amended and restated in its entirety as follows:

     

      The Reporting Persons used a total of approximately $24,275,566 (excluding brokerage commissions) to acquire the shares of Common Stock reported herein.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
    Item 5(c) is hereby amended and supplemented, as follows:

     

    (c) Information concerning transactions in the Shares effected by the Reporting Persons since the filing of the Original Schedule 13D is set forth in Annex B hereto and is incorporated herein by reference. All of the transactions in the shares of Common Stock listed therein were effected in the open market through various brokerage entities.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
    Item 6 is hereby amended and restated in its entirety as follows:

     

     

    The Reporting Persons’ response to Item 4 is incorporated by reference into this Item 6.

     

    The Reporting Persons are parties to an agreement with respect to the joint filing of this Schedule 13D and any amendments thereto. A copy of such agreement is attached as Exhibit 99.1 to this Schedule 13D and is incorporated by reference herein.

     

      Other than as described herein, there are no contracts, arrangements, understandings or relationship among the Reporting Persons or between the Reporting Persons and any other person with respect to the securities of the Issuer.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS
    Item 7 is hereby amended and supplemented by the addition of the following:

     

    Exhibit 99.1:

    Joint Filing Agreement

     

    ANNEX B: Transactions in the Shares of the Issuer Since the Filing of the Original Schedule 13D.

     

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: September 11, 2023

     

      CALIGAN PARTNERS LP
       
       
      By: /s/ David Johnson
      Name:   David Johnson
      Title: Managing Partner
       
       
      /s/ David Johnson
      DAVID JOHNSON

     

     

    ANNEX B

     

    Transactions in the Shares of the Issuer Since the Filing of the Original Schedule 13D

     

    The following table sets forth all transactions in the shares of Common Stock reported herein effected since the filing of the Original Schedule 13D. Except as noted below, all such transactions were effected by the Reporting Persons in the open market through brokers and the price per share excludes commissions. Where a price range is provided in the column titled “Price Range ($)”, the price reported in the column titled “Price Per Share ($)” is a weighted average price. These shares of Common Stock were sold or purchased in multiple transactions at prices between the price ranges indicated in the column titled “Price Range ($)”. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold or purchased at each separate price.

     

     

    Trade Date Shares Purchased (Sold) Price Per Share ($) Price Range ($)
           
    8/17/2023 30,000 18.61 18.12 – 18.97
    8/18/2023 10,000 18.79 18.29 – 19.05
    8/28/2023 10,000 18.18 18.00 – 18.66
    9/5/2023 3,727 16.94 16.60 – 17.91
    9/6/2023 20,000 17.24 17.00 – 17.83
    9/7/2023 68,051 17.16 16.88 – 17.40
    9/8/2023 37,496 17.05 16.54 – 17.39
           
           

     

     

    EXHIBIT 99.1

     

    Joint Filing Agreement

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he, she or it knows that such information is inaccurate.

     

    Dated: August 17, 2023

      

      CALIGAN PARTNERS LP
         
         
      By: /s/ David Johnson
      Name:   David Johnson
      Title: Managing Partner
       
       
      /s/ David Johnson
      DAVID JOHNSON

     

     

    Get the next $ANIK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    SEC Filings

    See more
    • Anika Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

      6/24/25 5:01:26 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Anika Therapeutics Inc.

      10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

      5/9/25 2:30:08 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

      5/9/25 7:20:20 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation

      7/3/25 5:00:55 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation

      6/5/25 5:00:54 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the comp

      5/12/25 5:00:24 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vogt Susan L N was granted 14,164 shares, increasing direct ownership by 39% to 50,213 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:14:37 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Director Richard Stephen was granted 14,164 shares, increasing direct ownership by 42% to 47,871 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:13:40 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Director Larsen Glenn R. was granted 14,164 shares, increasing direct ownership by 39% to 50,258 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:13:04 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

      B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Barrington Research reiterated coverage on Anika Therapeutics with a new price target

      Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

      11/1/24 10:25:08 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics upgraded by Barrington Research with a new price target

      Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

      8/14/23 9:16:10 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Financials

    Live finance-specific insights

    See more
    • Anika Reports First Quarter 2025 Financial Results

      First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven

      5/9/25 7:05:26 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

      BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.co

      4/25/25 9:00:59 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Fourth Quarter and Full Year 2024 Financial Results

      Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthoped

      3/12/25 4:05:37 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

      SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      11/8/24 2:17:24 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

      SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      5/30/24 4:31:25 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

      SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      3/6/24 7:30:09 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    See more
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care
    • Anika Enters into Cooperation Agreement with Caligan Partners

      Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

      5/28/24 4:05:00 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Announces CFO Transition

      BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

      5/8/24 4:08:54 PM ET
      $ANIK
      $VSEC
      Medical/Dental Instruments
      Health Care
      Military/Government/Technical
      Consumer Discretionary